 Connection
Paul Bunn to Administration, Oral
This is a "connection" page, showing publications Paul Bunn has written about Administration, Oral.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.117 |
|
|
|
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.042
-
Bunn PA, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):87-94.
Score: 0.042
-
Mascaux C, Feser WJ, Lewis MT, Bar?n AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila). 2013 Feb; 6(2):100-8.
Score: 0.022
-
BUNN PA, CRONK GA. [A comparison of blood concentrations following the oral administration of tetracycline hydrochloride, tetracycline phosphate complex, and various tetracycline mixtures]. Antibiotic Med Clin Ther (New York). 1958 Jun; 5(6):379-423.
Score: 0.008
-
Krasnow S, Bunn PA, Ihde DC, Matthews MJ, Cohen MH, Eddy J, Minna JD. ICRF-159 in advanced gastric cancer. Absence of activity. Am J Clin Oncol. 1982 Dec; 5(6):635-9.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|